UroAlert - GU Oncology Weekly

September 26, 2024

Videos

Peer-to-Peer Clinical Conversations

UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad

Arun Azad

Neeraj Agarwal interviews Arun Azad about the UpFrontPSMA study.

Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky

Matthew Galsky

Matthew Galsky discusses preliminary results from the RC48G001 Study Cohort C, evaluating disitamab vedotin plus pembrolizumab in HER2-expressing metastatic urothelial cancer.

Beyond the Abstracts

A Genetic Basis for Sex Differences in Xp11 Translocation Renal Cell Carcinoma - Beyond the Abstract

Use of Bladder Epicheck® in the Follow-up of High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Literature Review - Beyond the Abstract

Conference Coverage

ESMO 2024: Radioligand Theranostics in Prostate Cancer: Status Quo and New Developments

ESMO 2024: Non-Clear Cell RCC

ESMO 2024: Invited Discussant: Improving Outcomes of Localized Urothelial Cancer

ESMO 2024: Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma vs Observation: Extended Follow-up DFS Results and Metastatic Disease Recurrence Distribution

ESMO 2024: CARE1 Pragmatic Clinical Trial - First Line Randomised Study Platform to Optimize Treatment in Patients with Metastatic Renal Cell Carcinoma

ESMO 2024: DLL-3 Targeted Therapy for Neuroendocrine Prostate Cancer

ESMO 2024: T Cell Engagers in Prostate Cancer

ESMO 2024: Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC Patients

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

An overview of immune checkpoint inhibitor toxicities in bladder cancer.

The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee.

Clinical use of nadofaragene firadenovec-vncg.

Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.

Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder Cancer.

Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.

HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.

Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.

TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods.

APPRAISE-AI Tool for Quantitative Evaluation of AI Studies for Clinical Decision Support.

Quantitative Nuclear Grading: An Objective, Artificial Intelligence-Facilitated Foundation for Grading Noninvasive Papillary Urothelial Carcinoma.

Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials.

Investigating the association between blue light cystoscopy utilization and social determinants of health.

Diagnostic accuracy of cytology and urine methylation test in patients with non-muscle invasive bladder cancer: a systematic review and meta-analysis.

The Feasibility and Efficacy of Multiparametric MRI for Staging Bladder Cancer - Expert Commentary

Penile & Urethral Cancers

Global burden of penile cancer: A review of health disparities for a rare disease.

Factors affecting the postoperative prognosis of penile cancer.

Renal Cancer

Prognostic models for predicting oncological outcomes after surgical resection of a nonmetastatic renal cancer: A critical review of current literature.

Evaluating the Impact of a Shared Decision-making Intervention for Patients with Renal Cell Carcinoma: The SDM-RCC Study Protocol.

CT-Guided Online Adaptive Radiotherapy Delivered via Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) for a Bulky Thoracic and Abdominal Mass in Oligometastatic Renal Cell Carcinoma.

Clinical Impact of the CARMENA Trial on Cytoreductive Nephrectomy Practices in the USA: A Difference-in-differences Analysis.

Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma.

Development and validation of a CT based radiomics nomogram for preoperative prediction of ISUP/WHO grading in renal clear cell carcinoma.

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Renal Mass Biopsy is Associated With Fewer Radical Nephrectomies for Benign or Indolent Disease, Particularly for T1b Renal Masses.

Chinese expert consensus on the systemic treatment of advanced clear cell renal cell carcinoma (2024 edition).

Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists.

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

Prostate Cancer

Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival.

Prognostic significance of the PI-RADS score in men with prostate cancer undergoing radical prostatectomy.

Online Adaptive Proton Therapy Facilitated by Artificial Intelligence-based Auto Segmentation in Pencil Beam Scanning Proton Therapy: Prostate oAPT in PBSPT.

A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer.

Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.

Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval.

Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.

Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer.

Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.

Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial.

Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?

Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study.

Whole-body MRI for staging prostate cancer: a narrative review.

Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.

Virtual reality as an adjunct to traditional patient counseling in patients with newly-diagnosed localized prostate cancer.

American Radium Society Appropriate Use Criteria for the Workup and Treatment of Local Intraprostatic Recurrence of Prostate Cancer Following Definitive Radiotherapy.

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends.

A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.

Beyond Medical Bills: The Indirect Costs of Prostate Cancer.

Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.

Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costs.

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.

Does sexual rehabilitation work for gay and bisexual prostate cancer patients? Acceptability, feasibility, and efficacy results from the Restore-2 randomized controlled trial.

Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France.

Secondary Cancer in Prostate Cancer Patients Treated With Advanced External Beam Radiation Therapy.

5-α Reductase Inhibitors and Prostate Cancer Mortality - Beyond the Abstract

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial.

Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation Therapy.

Stereotactic radiotherapy for localized prostate cancer: 10-year outcomes from three prospective trials.

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.

A Common Culprit Drives Prostate Cancer Progression

Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System - Beyond the Abstract

Cost-Utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care - Beyond the Abstract

Neurologic Symptoms after 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience - Beyond the Abstract

Upper Tract Tumors

Strategies to reduce bladder tumor recurrences following surgery for upper tract urothelial carcinoma.

Testicular Cancer

Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection.

First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).

Aging-related biomarkers in testicular cancer survivors after different oncologic treatments.

The expression of programmed cell death ligand 1 (PD-L1) involves in the clinicopathologic characteristics and prognostic implications of testicular germ cell tumor (TGCT): a systematic review and meta-analysis.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC